GB1565830A - Varicella zoster virus vaccine - Google Patents
Varicella zoster virus vaccine Download PDFInfo
- Publication number
- GB1565830A GB1565830A GB53537/76A GB5353776A GB1565830A GB 1565830 A GB1565830 A GB 1565830A GB 53537/76 A GB53537/76 A GB 53537/76A GB 5353776 A GB5353776 A GB 5353776A GB 1565830 A GB1565830 A GB 1565830A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- varicella
- vaccine
- strain
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 title claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 25
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 18
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 210000001835 viscera Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000007514 Herpes zoster Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 230000007419 viral reactivation Effects 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000000394 Varicella Zoster Encephalitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001201 live attenuated varicella Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 239000004239 monopotassium glutamate Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- HQEROMHPIOLGCB-DFWYDOINSA-M potassium;(2s)-2-aminopentanedioate;hydron Chemical compound [K+].[O-]C(=O)[C@@H](N)CCC(O)=O HQEROMHPIOLGCB-DFWYDOINSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/821—Drug, bio-affecting and body treating compositions involving temperature-sensitive mutant virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/644,787 US4008317A (en) | 1975-12-29 | 1975-12-29 | Varicella-zoster virus vaccine and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1565830A true GB1565830A (en) | 1980-04-23 |
Family
ID=24586321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB53537/76A Expired GB1565830A (en) | 1975-12-29 | 1976-12-22 | Varicella zoster virus vaccine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4008317A (enExample) |
| JP (1) | JPS5282721A (enExample) |
| BE (1) | BE849897A (enExample) |
| DE (1) | DE2655691C2 (enExample) |
| FR (1) | FR2336944A1 (enExample) |
| GB (1) | GB1565830A (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043847A4 (en) * | 1980-01-25 | 1982-07-06 | Wistar Inst | HIGHLY ATTENUED CHICKENPOX VIRUS VACCINE AND PRODUCTION THEREOF. |
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| US4714678A (en) * | 1982-10-13 | 1987-12-22 | Smithkline-Rit | Temperature sensitive strain of bovine viral diarrhoea virus |
| IT1213254B (it) * | 1984-12-06 | 1989-12-14 | Boehringer Biochemia Srl | Metodo diagnostico per la valutazione di parametri clinici mediante prelievo diretto dimateriali biologici e dispositivoper la sua attuazione. |
| ES2150906T3 (es) | 1990-10-04 | 2000-12-16 | Res Corp Technologies Inc | Antigeno del virus varicella-zoster. |
| US5824319A (en) * | 1990-10-04 | 1998-10-20 | Research Corporation Technologies, Inc. | Varicella-zoster virus antigen |
| JP4562812B2 (ja) * | 1992-07-17 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法 |
| US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
| US7666082B2 (en) * | 2004-05-07 | 2010-02-23 | Gamelogic Inc. | Method and apparatus for conducting a game of chance |
| US10350289B2 (en) | 2013-09-05 | 2019-07-16 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
-
1975
- 1975-12-29 US US05/644,787 patent/US4008317A/en not_active Expired - Lifetime
-
1976
- 1976-12-08 DE DE2655691A patent/DE2655691C2/de not_active Expired
- 1976-12-22 GB GB53537/76A patent/GB1565830A/en not_active Expired
- 1976-12-24 JP JP15733876A patent/JPS5282721A/ja active Granted
- 1976-12-28 BE BE173669A patent/BE849897A/xx not_active IP Right Cessation
- 1976-12-29 FR FR7639469A patent/FR2336944A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4008317A (en) | 1977-02-15 |
| JPS5282721A (en) | 1977-07-11 |
| FR2336944B1 (enExample) | 1980-07-18 |
| FR2336944A1 (fr) | 1977-07-29 |
| BE849897A (fr) | 1977-06-28 |
| DE2655691C2 (de) | 1985-08-14 |
| JPS624370B2 (enExample) | 1987-01-30 |
| DE2655691A1 (de) | 1977-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69125925T2 (de) | Rekombinante herpes simplex virus impfstoffe und methoden | |
| DE69325370T2 (de) | Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen | |
| DE69229543T2 (de) | Deletionsvarianten des herpes simplex virus-1 und entsprechende impfstoffe | |
| US4008317A (en) | Varicella-zoster virus vaccine and preparation thereof | |
| US3992522A (en) | Temperature-sensitive recombinant mutant viruses and a process for producing same | |
| US4053583A (en) | Live newcastle disease virus vaccines | |
| DE69330758T2 (de) | Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe | |
| CA1113860A (en) | Live newcastle disease virus vaccine | |
| DE69534993T2 (de) | Impfstoff aus abgeschwächten hundeparvoviren | |
| US3962424A (en) | Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them | |
| US4318903A (en) | Live influenza virus vaccine and the preparation thereof | |
| CA1039186A (en) | Temperature sensitive and non-pathogenic bovine adenovirus | |
| DE69323130T2 (de) | Avirulenter Tollwut-Impfstoff | |
| US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
| Morita et al. | Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| DE69328341T2 (de) | Impfstoff gegen infektiöse Bursal-Krankheit | |
| EP0351908B1 (en) | Live newcastle disease virus vacccines | |
| EP0351901B1 (en) | Swine kidney cell culture, and its use in vaccine production | |
| McCrumb Jr et al. | Clinical trials with living attenuated measles virus vaccines | |
| EP0427767B1 (en) | Vaccine | |
| EP0119025B1 (en) | Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis | |
| US4287178A (en) | Feline rhinotracheitis vaccine and production and use thereof | |
| US4618493A (en) | Temperature sensitive strains of bovine viral diarrhoea virus, preparation thereof and vaccines containing them | |
| Carmichael et al. | Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |